<DOC>
	<DOCNO>NCT00422097</DOCNO>
	<brief_summary>This study determine maximum tolerate dose oral ixabepilone administer 5 successive day every 21 day participant advanced cancer . The safety , tolerability , pharmacokinetics ixabepilone body study . In addition , study assess preliminary evidence effect food famotidine pharmacokinetics oral ixabepilone .</brief_summary>
	<brief_title>A Phase I Study Oral Ixabepilone Subjects With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Confirmed diagnosis solid tumor malignancy unresponsive current treatment option Measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors Lapse least 1 week since minor surgery least 3 week since major surgery radiation therapy Eastern Cooperative Oncology Group performance status 01 Lapse least 4 week since immunotherapy chemotherapy Negative pregnancy test result within 72 hour study drug administration woman childbearing potential ( WOCBP ) WOCBP unable unwilling use birth control study 4 week study completion Women pregnant breastfeed Fertile men use effective birth control partner WOCBP Gastrointestinal ( GI ) disease GI tract surgery could impact drug absorption Inability swallow capsule Inability venipunctured tolerate venous access Known symptomatic brain metastasis Common Terminology Criteria Adverse Events Grade 2 great neuropathy history Grade 3 great neuropathy Psychiatric condition inhibit compliance protocol requirement Uncontrolled medical disorder active infection would impair participant 's ability receive protocol therapy whose control may jeopardize study treatment protocol Inadequate hematologic , hepatic , renal function History significant drug allergy Previous exposure ixabepilone Exposure investigational drug placebo within 4 week enrollment Concurrent chemotherapy regimen Use cytochrome P4503A4 inhibitor inducer within 2 week treatment initiation ( unless approve medical monitor ) Use steroid ( except antiemetic ) Prisoners subject involuntarily detain treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>